Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, El-Balat A, Marme F, De Gregorio N, Baumannn K, Mahner S, Meier W, Park-Simon TW, Grischke EM, Hillemanns P, Hilpert F, Lueck HJ, Kimmig R, Gropp-Meier M, Burges A, Jackisch C, Schroeder W, Pfisterer J (2020)
Publication Type: Conference contribution
Publication year: 2020
Publisher: KARGER
City/Town: BASEL
Pages Range: 87-87
Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT
APA:
Hanker, L., Harter, P., Sehoul, L., Rau, J., Canzler, U., Schmalfeldt, B.,... Pfisterer, J. (2020). Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG). In ONCOLOGY RESEARCH AND TREATMENT (pp. 87-87). BASEL: KARGER.
MLA:
Hanker, Lars, et al. "Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2020. 87-87.
BibTeX: Download